



## Medidata Delivers a Decade of AI Leadership to 500+ Clinical Studies and Growing

*Powered by Medidata's AI technologies, complex clinical data is transformed, delivering significantly faster study build and shorter trial timelines*

**New York – Feb. 11, 2026 –** [Medidata](#), a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, continues to accelerate clinical trial success for biopharmaceutical and medtech customers through enhanced AI-powered capabilities. Its AI technology has been scaled across the [Medidata Platform](#), benefiting over 500 clinical studies in the last decade, including more than 120 AI-supported studies starting in 2025.

Building on its established AI foundation, Medidata continues to seamlessly weave intelligence into more solutions across its unified platform. The latest advancements include significant enhancements to [Medidata Designer](#) with the introduction of [Medidata AI Study Build](#). The new capability accelerates study builds by leveraging the study protocol and generative AI to configure [Medidata Rave EDC](#) and [Medidata eCOA](#) systems, drastically reducing the time required to move from protocol to start-up. This delivers faster study build times, dramatically speeding time-to-market for sponsors and critical decision-making for CROs.

“Leveraging our large clinical data set from more than 38,000 trials, Medidata's AI is redefining clinical trials, with its impact now evolving from pervasive embedding to quantifiable outcomes,” said [Lisa Moneymaker](#), chief strategy officer, Medidata. “By prioritizing clinically-fluent, regulatory-grade AI to drive results across the trial lifecycle, we are helping our customers turn complexity into clarity and data into decisive action. Our foundational AI engine delivers platform capabilities that allow development teams to focus on resources for advancing patient care.”

To deliver truly intelligent automation, Medidata is accelerating the [expansion of Dot](#), its core AI orchestrator that coordinates and connects the actions of domain specific AI Companions across the platform. The visual presence of Dot enables customers to instantly recognize and access the power of AI built into every step of the clinical trial process. This clear visibility accelerates the use of AI to advance new therapies to patients faster.

“As the life sciences industry increasingly moves toward embedded, enterprise AI solutions, Medidata's AI Study Build has the potential to transform complex database build processes and accelerate market access, while Dot ensures transparency and builds trust in the use of AI,” said Dr. Nimita Limaye, Research VP, Life Sciences R&D Strategy & Technology, at IDC.

To learn more about Medidata's AI capabilities, click [here](#).

### About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 37,000 trials and 11 million patients, Medidata offers industry-leading expertise, analytics-powered

insights, and one of the largest clinical trial data sets in the industry. More than 1 million registered users across approximately 2,300 customers trust Medidata's seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at [www.medidata.com](http://www.medidata.com). Listen to our latest podcast, *from Dreamers to Disruptors*, and follow us at @Medidata.

### **About Dassault Systèmes**

Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. With Dassault Systèmes' 3DEXPERIENCE platform, 370,000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit: [www.3ds.com](http://www.3ds.com).

### **Contact:**

**For interviews and questions, please contact Medidata PR**

[Medidata.PR@3ds.com](mailto:Medidata.PR@3ds.com)

### **Analyst Relations**

[Medidata.AR@3ds.com](mailto:Medidata.AR@3ds.com)